Superworth

CareDx revenue CDNA

Sales by quarter and over the last twelve months, from 2013.

Last 12 months, to Sep 30, 2026
$497.4M
Latest quarter, Q3 FY26
$139.4M
+39% on a year earlier
Fiscal year 2025
$379.8M
+14% on the year before

CareDx's revenue was $497.4M over the twelve months to Sep 30, 2026, up 39% on a year earlier.

In its latest quarter, Q3 FY26, it was $139.4M, up 39% on the same quarter a year before.

Over the five fiscal years to FY2025 it grew 15% a year on average.

Revenue over time

Open the interactive chart, with overlays and comparisons

Fiscal year by fiscal year

Fiscal yearRevenueChange
FY2025$379.8M+14%
FY2024$333.8M+19%
FY2023$280.3M−13%
FY2022$321.8M+9%
FY2021$296.4M+54%
FY2020$192.2M+51%
FY2019$127.1M+66%
FY2018$76.6M+58%
FY2017$48.3M+19%
FY2016$40.6M+44%
FY2015$28.1M+3%
FY2014$27.3M+24%
FY2013$22.1Mn/a

Each fiscal year is the twelve months to its fourth quarter.

Quarter by quarter

QuarterEndedRevenueOn a year earlierLast 12 months
Q3 FY26$139.4M+39%$497.4M
Q2 FY26$131.9M+52%$458.1M
Q1 FY26$117.7M+39%$412.8M
Q4 FY25$108.4M+25%$379.8M
Q3 FY25$100.1M+21%$358M
Q2 FY25$86.7M−6%$340.8M
Q1 FY25$84.7M+18%$346.4M
Q4 FY24$86.6M+32%$333.8M
Q3 FY24$82.9M+23%$312.8M
Q2 FY24$92.3M+31%$297.1M
Q1 FY24$72M−7%$275.1M
Q4 FY23$65.6M−20%$280.3M

Against its peers

Companies in Medical - Diagnostics & Research nearest CareDx's size, closest first, today.

CompanyRevenue, 12 monthsGrowth
CDNACareDx$497.4M+39% a year
VCYTVeracyte$561.9M+17% a year
BLLNBillionToOne$397.4M+90% a year
LNTHLantheus$1.6B+2% a year
CAICaris Life Sciences$989.6M+85% a year
BIOBio-Rad Laboratories$2.6B+1% a year
RVTYRevvity$2.9B+4% a year
MEDPMedpace$2.8B+25% a year
DGXQuest Diagnostics$11.8B+9% a year
LHLabcorp$14.3B+6% a year
MTDMettler-Toledo International$4.1B+7% a year
Peer median$2.7B

Where CareDx ranks

What the revenue tells you

Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.

Growing revenue with shrinking margins is a warning, not a win.

More on CareDx

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.